Yahoo Web Search

Search results

  1. Feb 9, 2023 · Full-Year Financial Results. Baxter’s 2022 worldwide sales totaled $15.1 billion, an increase of 18% on a reported basis, 23% on a constant currency basis and 2% on an operational basis. Operational sales for the full year exclude the impacts of foreign exchange and the December 2021 acquisition of Hillrom.

  2. Feb 17, 2022 · For full-year 2021, net income attributable to Baxter totaled $1.3 billion, or $2.53 per diluted share, increasing 19% on a U.S. GAAP basis compared to the prior year.

  3. Feb 9, 2023 · The accompanying schedules include additional details on sales performance by product categories and segments. For full-year 2022, net income (loss) attributable to Baxter totaled ($2.4 billion), or ($4.83) per diluted share on a U.S. GAAP basis.

  4. Feb 4, 2021 · For full-year 2021: Baxter expects sales growth of 7% to 8% on a reported basis and 4% to 5% on a constant currency basis. The company expects U.S. GAAP earnings of $2.91 to $2.99 per diluted share and adjusted earnings, before special items, of $3.35 to $3.43 per diluted share.

  5. Feb 17, 2022 · On an adjusted basis, 2021 net income attributable to Baxter totaled $1.8 billion, or $3.61 per diluted share, an increase of 17% compared to the prior-year period. Adjusted results for full-year 2021 include a contribution to earnings of $0.08 per diluted share from Hillrom.

  6. Information regarding Baxters recent announcements, upcoming & past events, and other useful resources for investors. Annual Reports & Proxy. Baxter's Annual Chairman Letter, Proxy Statement and Form 10-K filings sorted by year. Financial Schedules. Financial schedules and Non-GAAP reconciliations by quarter. SEC Filings

  7. People also ask

  8. Feb 17, 2022 · For full year 2022, we expect global sales growth of 24% to 25% on a reported basis, 26% to 27% on a constant currency basis and approximately 4% on an operational basis.

  1. People also search for